Russell Investments Group, Ltd. Ascendis Pharma A/S Transaction History

Russell Investments Group, Ltd.

$66.8 Billion
Q3 2024

A detailed history of Russell Investments Group, Ltd. transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Russell Investments Group, Ltd. holds 3,208 shares of ASND stock, worth $435,325. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,208

Previous 3,208 -0.0%

Holding current value

$435,325

Previous $437,000 9.61%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 05, 2024	SELL	$86.1 - $127.36 $358,692 - $530,581	-4,166 Reduced 56.5%	3,208 $404,000
Q3 2023 Nov 13, 2023	SELL	$86.5 - $103.97 $3.48 Million - $4.19 Million	-40,252 Reduced 84.52%	7,374 $690,000
Q2 2023 Aug 10, 2023	SELL	$69.96 - $97.84 $460,126 - $643,493	-6,577 Reduced 12.13%	47,626 $4.25 Million
Q1 2023 May 09, 2023	SELL	$104.9 - $126.78 $499,324 - $603,472	-4,760 Reduced 8.07%	54,203 $5.81 Million
Q4 2022 Feb 08, 2023	SELL	$99.42 - $131.97 $719,701 - $955,330	-7,239 Reduced 10.93%	58,963 $7.2 Million
Q3 2022 Nov 04, 2022	BUY	$84.03 - $110.23 $1.43 Million - $1.87 Million	16,970 Added 34.47%	66,202 $6.83 Million
Q2 2022 Jul 29, 2022	BUY	$78.08 - $117.61 $971,861 - $1.46 Million	12,447 Added 33.84%	49,232 $4.58 Million
Q1 2022 May 05, 2022	BUY	$102.18 - $135.75 $1.06 Million - $1.4 Million	10,332 Added 39.06%	36,785 $4.32 Million
Q4 2021 Jan 21, 2022	BUY	$127.1 - $169.66 $126,845 - $169,320	998 Added 3.92%	26,453 $3.56 Million
Q3 2021 Nov 08, 2021	BUY	$112.67 - $176.92 $587,461 - $922,460	5,214 Added 25.76%	25,455 $4.06 Million
Q2 2021 Aug 04, 2021	BUY	$121.62 - $145.29 $2.46 Million - $2.94 Million	20,241 New	20,241 $2.66 Million

Others Institutions Holding ASND

# of Institutions

244

Shares Held

58.8M

Call Options Held

250K

Put Options Held

377K

View Full List

About Ascendis Pharma A/S

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $7.57B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

More about ASND

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Russell Investments Group, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Russell Investments Group, Ltd. with notifications on news.

Account

Russell Investments Group, Ltd. Ascendis Pharma A/S Transaction History